CybernaX Secures Licensing Deal with Merck KGaA for Advanced Lipid Storage Technology
CybernaX, a biotechnology company based in Nanjing, has entered into a comprehensive licensing agreement with...
Shanghai Vitalgen BioPharma Partners with Novoprotein to Commercialize AaCas12bMax Gene Editor
Shanghai Vitalgen BioPharma Co., Ltd, a specialist in cell and gene therapy based in China,...
Walvax Biotechnology’s HPV Vaccine Price Cut Sparks Potential Market Price War in China
Walvax Biotechnology Co., Ltd (SHE: 300142) has significantly reduced the price of its bivalent human...
Mabwell Bioscience Partners with Cristália for Biosimilar Denosumab in Brazil
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has entered...
Daiichi Sankyo and MSD Broaden Partnership to Co-Develop T-Cell Engager MK-6079
Daiichi Sankyo (TYO: 4568), a Japanese pharmaceutical company, has announced an expansion of its strategic...
Bayer AG’s Q2 2024 Global Group Sales Rise 3.1%, Driven by Pharmaceuticals and Consumer Healthcare
Bayer AG (OTCMKTS: BAYZF), a multinational pharmaceutical and life sciences company headquartered in Germany, has...
Antengene’s Xpovio Receives NDA Approval in Malaysia for Multiple Myeloma Treatment
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced the approval...
Israeli Hair Transplant Innovator Hairstetics Launches First Procedure in Asia at Hainan Hospital
Hairstetics, an Israeli innovator in the non-absorbable polyamide hair transplant sector, has achieved a milestone...
Hotgen Biotech’s SGC001 Receives NMPA Approval for Clinical Trials in Myocardial Infarction
Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that...
Suzhou Zelgen Biopharmaceuticals’ ZG005 Receives NMPA Approval for Clinical Trials in Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
Gan & Lee Pharmaceuticals Gets FDA Green Light for Phase I Clinical Trial of Insulin Aspart Biosimilar
Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company based in China, has received...
Luye Pharma’s LY03020 Receives NMPA Approval for Schizophrenia and Alzheimer’s Psychosis Treatment
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced that it has received...
CMS’s Methotrexate Injection Gains NMPA Approval for Active Rheumatoid Arthritis Treatment
China Medical System Holdings (CMS; HKG: 0867) has received approval from the National Medical Products...
Northeast Pharmaceutical to Acquire Majority Stake in Cell Therapy Specialist Dingcheng Taiyuan
Northeast Pharmaceutical Co., Ltd (SHE: 000597), a Chinese pharmaceutical company, has announced plans to acquire...
Sihuan Pharmaceutical Gains Exclusive Rights to Cellontech’s Cartilage Treatment in China
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a leading pharmaceutical company in China, has entered...
Takeda’s Vonicog Alfa Receives NMPA Approval for Von Willebrand Disease Treatment in China
Takeda Pharmaceutical Company Limited (TYO: 4502 / NYSE: TAK), a leading Japanese pharmaceutical company, has...
BioNTech Ends Collaboration with Genmab on Acasunlimab Development
Genmab A/S (NASDAQ: GMAB), a Danish biotechnology company, has announced that its German partner BioNTech...
Eisai’s Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling
Eisai Co., Ltd (TYO: 4523), a prominent Japanese pharmaceutical company, has released its financial results...
Daiichi Sankyo Reports 24.3% YOY Revenue Growth, Driven by Enhertu and Lixiana
Daiichi Sankyo (TYO: 4568), a leading pharmaceutical company in Japan, reported a significant year-on-year (YOY)...
Shionogi Files for Chinese Approval of Cefiderocol to Combat Gram-Negative Bacterial Infections
Shionogi Co., Ltd, a prominent Japanese pharmaceutical company, has announced the filing of a New...